Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
What adjuvant therapy would you recommend for a patient with upper tract urothelial carcinoma with neuroendocrine differentiation?
Related Questions
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
What are your top takeaways from ASCO GU 2024?
Would you offer adjuvant immunotherapy in a patient with high risk RCC with new/worsening post-op renal dysfunction and CrCl<30?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
Do you offer neoadjuvant chemotherapy to nested variant urothelial carcinoma (NVUC) of the bladder?
How do you manage anemia associated with belzutifan therapy?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?
